Blood Cancer Diagnostics Market: Industry Demand, Analysis And Future Trends 2030

 

The global Blood Cancer Diagnostics Market size is expected to reach USD 16.04 billion by 2030, registering a CAGR of 6.87% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of blood malignancies, such as leukemia, lymphoma, and myeloma. The market is further expected to grow significantly due to the increasing elderly population, which is more susceptible to chronic diseases, including blood cancer. In addition, technological advancements, including NGS and other molecular diagnostic techniques, are improving the accuracy & efficiency of diagnosis, which is likely to drive the market over the forecast period.

Over the past decade, significant advancements have been made in approaches to blood cancer diagnostics, all aimed at reducing the growing incidence of diseases and their mortality. While these advancements have been well-documented to increase early cancer detection, there have been considerable advancements. For instance, NGS has enabled the analysis of the entire genome of cancer cells, providing insights into genetic mutations that guide precise diagnosis and tailored treatments. In October 2022, OGT, a Sysmex group, introduced a range of new offerings to augment its expanding NGS product suite. Notably, the SureSeq Myeloid Plus panel was designed to identify genetic mutations associated with various Myeloid disorders, enhancing the company’s capabilities in this critical area of research.

Molecular imaging techniques, such as SPECT/CT, PET, and flow cytometry, utilize molecular imaging agents to detect indicative molecular markers at different disease stages, aiding detection & monitoring. Such advancements in imaging technologies offer improved accuracy and early detection capabilities, driving the market. The global players are introducing automatic imaging tests and systems to boost their market share. For instance, in May 2023, Sysmex Corporation announced the launch of the Clinical Flow Cytometry System in Japan. The system includes Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products. This system enables laboratories to automate the entire process of flow cytometry testing, from sample preparation to the reporting of measurement results, contributing to higher efficiency & testing standardization.

Governments across the world have recognized the immense healthcare burden posed by rising incidences, including hematological malignancies such as leukemia & lymphoma. In response, many countries have launched comprehensive national cancer control programs that prioritize early detection and screening efforts. For instance, the American Association of Cancer Research recently launched the Beau Biden Cancer Moonshot initiative to accelerate cancer research and make preventive screening more accessible & affordable for U.S. citizens.

Some of the key players in the market are Illumina, InVivoScribe, Ipsogen (Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories and others. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in September 2023, Adaptive Technologies launched Epic integration for clonoSEQ, a molecular diagnostic test for MRD monitoring in blood cancers. This integration allows healthcare providers to order and review clonoSEQ test results directly within Epic's EHR system, streamlining clinical decision-making and improving patient care. 

List of Key Players in the Blood Cancer Diagnostics Market

• Quest Diagnostics
• Illumina
• InVivoScribe
• Ipsogen (Qiagen)
• Asuragen(Bio-Techne)
• Danaher Corporation
• Abbott
• Sequenta (Adaptive biotechnologies)
• SkylineDx
• Bio-Rad Laboratories
• Alercell
• Sophia Genetics

Request a free sample copy or view report summary: Blood Cancer Diagnostics Market Report

Blood Cancer Diagnostics Market Report Highlights

• Based on product, the assay kits and reagents accounted for the largest revenue share of the blood cancer diagnostics market in 2024. This high share is attributable to assay kits & reagents being designed to detect specific biomarkers, genetic mutations, and other indicators, enabling healthcare professionals to diagnose & treat the disease more effectively
• Based on tests, blood tests segment dominated the market and accounted for the largest share in 2024. This can be attributed to increasing innovation and availability of blood test kits for blood cancer detection

• Based on end use, hospitals and clinics dominated the market with the largest share of blood cancer diagnostics market in 2024. This is attributable to growing demand in forensic labs and hospital medical labs for disease diagnosis, blood cell counts, blood typing. Furthermore, Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals aim to provide a wide range of services in their settings

• North America dominated the market due to the presence of a large number of major market players, North America has a high prevalence of chronic diseases like leukemia These diseases require regular monitoring and diagnostic testing, fueling the demand for advanced diagnostic tools and technologies
• Asia Pacific is expected to witness the fastest growth over the forecast period from 2025 to 2030, due to the presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities

Blood Cancer Diagnostics Market Segmentation 

Grand View Research has segmented the global blood cancer diagnostics market based on product, test, end-use, and region:

Blood Cancer Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments
• Assay Kits and Reagents

Blood Cancer Diagnostics Test Outlook (Revenue, USD Million, 2018 - 2030)

• Blood Tests
• Imaging Tests
• Biopsy
• Molecular Test

Blood Cancer Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals and Clinics
• Diagnostic Labs
• Research Institutes

Blood Cancer Diagnostics Regional Outlook (Revenue in USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Sweden
• Denmark
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East and Africa
• Saudi Arabia
• South Africa
• UAE
• Kuwait

About Us
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Postpartum Depression Drugs Market: Industry Demand, Analysis And Future Trends 2030

 The global Postpartum Depression Drugs Market is anticipated to reach USD 1.59 billion by 2030 and is expected to expand at a CAGR of 9.63% during the forecast period, according to a new report by Grand View Research, Inc. The increasing number of pregnancies worldwide primarily drives market growth. Many women suffer from postpartum depression (PPD) after having a baby and are at high risk of developing major depression later in life. According to the Cleveland Clinic Estimate, postpartum depression is a common condition that affects 1 in 7 women after giving birth to a child. Thus, rising government support for women who had childbirth and are suffering from mood disorders like PDD is expected to boost demand for drugs over the forecast period.

According to the Indian Association of Preventive & Social Medicine, every year, around 30 million women experience pregnancy, and 27 million women have live childbirths. In July 2022, the Government of India launched several schemes to support pregnant women, such as Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakaram (JSSK). Under these programs, the government offers free of cost treatment related to pregnancy, such as diagnostics, medicines, and other consumables. Thus, initiatives like JSSK and JSY support women in completing treatment such as postpartum depression, simultaneously driving market growth during the forecast period.

Another significant factor driving the adoption of postpartum depression drugs is rising healthcare expenditures, which help to improve infrastructure and improve patient access to healthcare facilities. According to the PETERSON-KFF Health System Tracker report, women spend around USD 18,865 annually on pregnancy, childbirth, and postpartum treatment. There is significant variation. around this, spending and costs vary significantly by region worldwide. The increasing access of women to PPD drug treatment is anticipated to drive market growth in the coming years.

Request a free sample copy or view report summary: Postpartum Depression Drugs Market Report

Postpartum Depression Drugs Market Report Highlights

• The postpartum anxiety segment held the largest share of the market in 2023. This can be attributed to the disease's high treatment rate and growing prevalence in developed and developing countries.
• Based on the treatment type, the hormonal therapy segment is expected to grow at the fastest CAGR during the forecast period.This can be attributed to the development and commercialization of new hormonal drugs and increased adoption by smaller hospitals and facilities for the treatment of PDD.
• In 2023, the oral segment held the largest share of the market based on the route of administration. This dominance can be attributed to the increase in the prevalence and incidence of disease worldwide, the large availability of products, and the rising demand for new generic oral drugs for treatment.
• The hospital pharmacy segment held the largest share of the market based on distribution channels in 2023. Hospital treatment rates, patient preference for hospitals over other healthcare settings for PDD treatment, and the increasing number of patients visiting hospitals.
• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising disease prevalence, and favorable regulatory environment.

Postpartum Depression Drugs Market Segmentation

Grand View Research has segmented the postpartum depression drugs market based on type, treatment, route of administration, distribution channel, and region:

Postpartum Depression Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)

• Postpartum Blues
• Postpartum Anxiety
• Postpartum Obsessive-Compulsive Disorder (OCD)
• Postpartum Post-Traumatic Stress Disorder (PTSD)
• Postpartum Panic Disorder
• Postpartum Psychosis

Postpartum Depression Drugs Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmacotherapy
• Hormonal Therapy
• Others

Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Parenteral
• Oral
• Others

Postpartum Depression Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy
• Retail Pharmacy
• Others (online pharmacy)

Postpartum Depression Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• Kuwait
• UAE

About Us
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Vaccine Delivery Devices Market Size is Anticipated to Grow at a CAGR of 7.6% By 2030

 

The global vaccine delivery devices market size is anticipated to reach USD 11.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 7.6% from 2025 to 2030. The market is primarily driven by growing immunization programs, financial support from government and non-government organizations, increasing vaccination initiatives and campaigns, and the rising prevalence of infectious diseases globally. Growing research in the field of vaccines and the development of new products are also contributing to the growth of the market.

The adoption of a needle-free approach for administering these products is gaining momentum due to the growing awareness and demand to avoid pain and injuries associated with the use of a needle stick. Data by the Centers for Disease Control and Prevention states that an estimated 385,000 sharp injuries including needle stick injuries occur every year in hospitals in the U.S. Advancing technologies in administering vaccines and their increasing adoption is propelling the market growth. The rising interest of various key players, national institutions, and organizations in novel delivery technologies is expected to further contribute to market growth.

The Covid-19 epidemic significantly boosted the market growth, especially due to the increasing demand for vaccination to tackle the spread of the virus. Increasing investment in Research & Development by vaccination device manufacturers as well as the governments has expanded the market significantly at an accelerated pace. Initiatives are undertaken by various regulatory authorities like UNICEF, Gavi, and WHO are also expected to boost the market growth.

Various governments and international organizations are increasingly investing in the development of vaccination programs. For instance, the U.K. government also announced funding of up to £1 million from its Global Challenges Research Fund through Medical Research Council to investigate the Zika virus and its transmission. Organizations such as GAVI Alliance, Bill & Melinda Gates Foundation, Path, and the WHO are actively involved in the field of vaccines. Many governments are also undertaking several immunization programs on priority.

List Of Key Players in the Vaccine Delivery Devices Market

• Becton Dickinson & Company
• Bioject Medical Technologies, Inc. (Inovio Pharmaceutical Inc.)
• PharmaJet
• Vaxxas
• Gerresheimer AG
• SCHOTT AG
• Corium International, Inc.
• 3M

Request a free sample copy or view the report summary: Vaccine Delivery Devices Market Report

Vaccine Delivery Devices Market Report Highlights

• By device, the syringes segment held the largest revenue share in 2024 due to the increasing vaccination programs, spreading immunization coverage, and technological advancements 
• By route of administration, intradermal vaccination dominated the market in 2024 as the majority of vaccines are given through this route owing to its advantages 
• North America dominated the global market in 2024 owing to the increasing awareness levels, high adoption of technology, and the rising prevalence of infectious diseases

Vaccine Delivery Devices Market Segmentation

Grand View Research has segmented the global vaccine delivery devices market report on the basis of device, route of administration, and region:

Vaccine Delivery Devices Device Outlook (Revenue, USD Million, 2018 - 2030)

• Syringes
• Jet Injectors
• Other Devices

Vaccine Delivery Devices Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Intradermal Vaccination
• Intramuscular Vaccination
• Subcutaneous Vaccination
• Other Vaccinations

Vaccine Delivery Devices Region Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

 

About Us
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Non-opioid Pain Treatment Market To Reach $70.30 Billion By 2030

The global Non-Opioid Pain Treatment Market size is expected to reach USD 70.30 billion by 2030, registering a CAGR of 7.69% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to an increase in the prevalence of inflammatory diseases coupled with the robust product pipeline of novel non-opioid analgesics. According to the Centers for Disease Control and Prevention (CDC), around 32.5 million people are living with osteoarthritis condition in the U.S. In addition, according to the Spondylitis Association of America, about 3.2 million adult people in the U.S. have some form of Spondyloarthritis. 

Initiatives are undertaken by government & nonprofit organizations to promote the usage of safer alternatives to opioids such as NSAIDs to address the increasing demand for pain relieving medicines. For instance, in February 2022, the U.S.FDA issued draft guidelines to provide recommendations to pharmaceutical companies for developing NSAIDs for the treatment of acute pain lasting for 30 days. This initiative was a part of the government’s “HHS Overdose Prevention Strategy” which focuses on the prevention, reduction, treatment, and recovery of patients from an opioid overdose. Such an initiative is projected to fuel demand for NSAID drugs over the forecast period. 

Key market players are aggressively developing innovative techniques to meet the growing demand for NSAIDs for the management of pain. For instance, in June 2021, the University of Arizona developed oxytocin analogs for the treatment of patients suffering from. It is a bioavailable non-opioid pain relief product with the potential for inhaled administration. The development of such an innovative product is anticipated to drive non-opioid analgesics treatment market growth. 

In September 2022, the U.S. FDA recommended avoiding non-opioid analgesics treatment in pregnancy at 20 weeks due to the high chances of kidney problems in unborn babies. Such initiatives from governments may limit the prescription of NSAIDs, thereby, restraining non-opioid pain treatment market growth. 

Companies are adopting strategies such as new product development, launches, and partnerships to increase the penetration of non-opioid analgesic products. For instance, in March 2022, Vertex Pharmaceuticals announced positive results of its phase 2 clinical trial non-opioid pill that showed a significant reduction in post-operative acute pain. Successful completion of trial and subsequent approval of products is anticipated to drive non-opioid analgesics treatment market growth during the forecast period. 

The market is highly competitive and the competition in the market is expected to be high during the forecast period due to the presence of a large number of players. Key companies manufacturing generic NSAID products include GSK plc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson & Johnson Services, Inc., amongst others. 

Request a free sample copy or view report summary: Non-opioid Pain Treatment Market Report

Non-opioid Pain Treatment Market Report Highlights

• In 2024, the NSAIDs segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period owing to the high demand for pain treatment and the commercialization of multiple NSAIDs in recent years
• Chronic pain was the accounted for highest share in 2024. Factors such as increasing product approvals, the high incidence rate of chronic pain, and high R&D initiatives for launching innovative NSAIDs products are leading to its dominance
• Based on route of administration type, the oral segment accounted for the highest share in 2024 owing to the easy administration and wide availability of orally administered NSAIDs products in the market
• Based on the distribution channel, retail pharmacies are expected to dominate the market with a 54.39% share in 2024. This dominance can be attributed to the presence of a large number of generic NSAIDs and their easy accessibility to patients due to the large presence of retail pharmacies network
• Asia Pacific region is expected to experience the fastest growth during the forecast period owing to an increase in penetration of NSAIDs products, rise in disposable income, and high disease prevalence of inflammatory diseases in developing countries 

Non-opioid Pain Treatment Market Segmentation

Grand View Research has segmented the global non-opioid pain treatment market based on drug class, pain, route of administration, distribution channels, and region:

Non-Opioid Pain Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• NSAIDs
• Non Selective NSAIDs
• Selective COX-2 Inhibitors
• Acetaminophen
• Local Anesthetics
• Other Drug Class

Non-Opioid Pain Treatment Pain Outlook (Revenue, USD Million, 2018 - 2030)

• Post-operative Pain
• Cancer Pain
• Chronic Pain
• Other Pain

Non-Opioid Pain Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral
• Topical
• Injectable
• Other Route of Administration

Non-Opioid Pain Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Non-Opioid Pain Treatment Regional Outlook (Revenue, USD Million, 2018–2030)

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• Kuwait
• UAE

 

About Us
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com